We studied the effects of veno-venous bypass (VVBP) circuit surface heparinization on the activation of the plasma defence systems (coagulation, fibrinolysis, kallikrein-kinin and complement) and leukocyte activation in a prospective randomized study in 20 patients during and 1 day after liver transplantation (OLT). To our knowledge, this is the first study of this kind where the possible benefits of surface heparinization of the VVBP circuit in OLT have been investigated. Twenty patients were randomized to either heparin-coated (HC) VVBP equipment or to otherwise identical noncoated (NC) circuits. Five blood samples were drawn during the OLT procedure: one just before VVBP, three during VVBP and one 5 min after portal venous reperfusion (PVR). A further sample was taken 1 day after the operation. Components of the blood coagulation, fibrinolytic and kallikrein-kinin systems were analysed using functional assays (chromogenic peptide substrate assays) or enzyme immunoassays (EIA). Complement system factors and granulocyte activation, represented by myeloperoxidase (MPO) release, were analyzed by EIA. Activation of the plasma defence systems occurred in both groups at an early stage during OLT and a further activation occurred 5 min after PVR. MPO levels were slightly elevated 5 min after PVR. However, no significant differences between the two groups were observed. Significant activation of the humoral defense systems was found in both groups during OLT. A considerably larger study, including at least 330 patients, is necessary to fully assess the possible benefits of surface heparinization of the VVBP circuit.
Get full access to this article
View all access options for this article.
References
1.
Moen O , Fosse E , Braten Jet al.Differences in blood activation related to roller/centrifugal pumps and heparin-coated/uncoated surfaces in a cardiopulmonary bypass model circuit . Perfusion1996; 11: 113-123 .
2.
Moen O , Fosse E , Dregelid Eet al.Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility . Ann Thorac Surg1996; 62: 1134-1140 .
3.
Fosse E , Moen O , Johnson Eet al.Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass . Ann Thorac Surg1994; 58: 472-477 .
4.
Moen O , Hogasen K , Fosse Eet al.Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass . Ann Thorac Surg1997; 63: 105-111 .
5.
Videm V , Mollnes TE , Garred P , Svennevig JL.Biocompatibility of extracorporeal circulation: in vitro comparison of heparin-coated and uncoated oxygenator circuits . J Thorac Cardiovasc Surg1991; 101: 654-660 .
6.
Videm V , Svennevig JL , Fosse Eet al.Reduced compliment activation with heparin-coated oxygenator and tubings in coronary bypass surgery . J Thorac Cardiovasc Surg1992; 103: 806-813 .
7.
Scholz T , Mathisen Ø , Bergan Aet al.Percutaneous technique for venovenous bypass including a heat exchanger is safe and reliable in liver transplantation . Transplant Int1997; 10: 180-184 .
8.
Aasen AO , Erichsen NS , Gallimore MJ , Amundsen E.Studies on components of the plasma kallikrein-kinin system in plasma samples from normal individuals and patients with septic shock . Adv Shock Res1980; 4: 1-10 .
9.
Aasen AO , Kierulf P , Strømme JH.Methodological considerations on chromogenic peptide substrate assays and application on automated analyzers . Acta Chir Scand1982; 509(suppl): 17-22 .
10.
Amundsen E , Gallimore MJ , Aasen AO , Larsbraaten M , Lyngaas K.Activation of human plasma prekallikrein: influence of activators, activation time and temperature and inhibitors . Thromb Res1978; 13: 625-636 .
11.
Garred P , Mollnes TE , Lea T.Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3 . Scand J Immunol1988; 27: 329-335 .
12.
Mollnes TE , Lea T , Frøland S , Harboe M.Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex . Scand J Immunol1985; 22: 197-202 .
13.
Videm V.Heparin in clinical doses “primes” granulocytes to subsequent activation as measured by myeloperoxidase release . Scand J Immunol1996; 43: 385-390 .
14.
Solberg R , Scholz T , Videm V , Okkenhaug C , Aasen AO.Heparin coating reduces cell activation and mediator release in an in vitro veno-venous bypass model for liver transplantation . Transplant Int1998; 11: 252-258 .
15.
Scholz T , Bäckman L , Mathisen Øet al.Activation of the plasma contact system and hemodynamic changes after graft revascularization in liver transplantation . Transplantation1995; 60: 36-40 .
16.
Wendel HP , Heller W , Gallimore MJ , Hoffmeister HE.Heparin-coated oxygenators significantly reduce contact system activation in an in vitro cardiopulmonary bypass model . Blood Coagulation Fibrinolysis1994; 5: 673-678 .
17.
Velthuis TE , Baufreton C , Jansen PG , Thijs CM , Hack CE , Sturk A.Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations . J Cardiovasc Surg1997; 114: 117-122 .
18.
Scholz T , Solberg R , Okkenhaug Cet al.Veno-venous bypass in liver transplantation: heparin-coated perfusion circuits reduce the activation of humoral defense systems in an in vitro model . Perfusion2000; 16: 285-292 .
19.
Roenholm E , Tomasdottir H , Runeborg Jet al.Complement system activation during orthotopic liver transplantation in man . Transplantation1994; 57: 1594-1597 .
20.
Tomasdottir H , Henriksson B-A , Bengtson J-P , Bengtsson A , Stenqvist O , Persson H.Complement activation during liver transplantation . Transplantation1993; 55: 799-802 .
21.
Mammen EF.Coagulation defects in liver disease . Med Clin North Am1994; 78: 545-554 .
Scholz T , Gallimore MJ , Bäckman Let al.Plasma proteolytic activity in liver transplant rejection . Transplant Int1999; 12: 100-107 .
24.
Himmelreich G , Jochum M , Bechstein WOet al.Mediators of leukocyte activation play a role in disseminated intravascular coagulation during orthotopic liver transplantation . Transplantation1994; 57: 354-358 .
